{"DataElement":{"publicId":"2960431","version":"1","preferredName":"Lineage Biomarker Occurrence Name","preferredDefinition":"Text name for a biomarker that is objectively measured and evaluated as an indicator of an individual's descent in a line from a common progenitor or source.","longName":"LING_MKR_OCC_NM","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2960422","version":"1","preferredName":"Lineage Biomarker Occurrence","preferredDefinition":"Descent in a line from a common progenitor or source._A characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. (From: FDA Guidance for Industry: Pharmacogenomic Data Submissions.)_An instance of something happening, such as an event or incident.","longName":"LING_MKR_OCC","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2960420","version":"1","preferredName":"Lineage Biomarker","preferredDefinition":"Descent in a line from a common progenitor or source.:Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc","longName":"C60792:C16342","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lineage","conceptCode":"C60792","definition":"Descent in a line from a common progenitor or source.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Biomarker","conceptCode":"C16342","definition":"A characteristic that can be objectively measured and serves as an indicator for normal biologic processes, pathogenic processes, state of health or disease, the risk for disease development and/or prognosis, or responsiveness to a particular therapeutic intervention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"781490A4-5176-A25E-E040-BB89AD432624","latestVersionIndicator":"Yes","beginDate":"2009-11-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-11","modifiedBy":"ONEDATA","dateModified":"2009-11-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2234856","version":"1","preferredName":"Occurrence","preferredDefinition":"Occurrence; an instance of something happening.","longName":"C25275","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9860F29-72B8-7421-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-14","modifiedBy":"ONEDATA","dateModified":"2005-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"781490A4-5184-A25E-E040-BB89AD432624","latestVersionIndicator":"Yes","beginDate":"2009-11-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-11","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2960424","version":"1","preferredName":"Lineage Biomarker Name","preferredDefinition":"Descent in a line from a common progenitor or source._Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc_The words or language units by which a thing is known.","longName":"LING_MKR_NM","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"DC marker (CD 11c)","valueDescription":"DC marker (CD 11c)","ValueMeaning":{"publicId":"2960425","version":"1","preferredName":"DC marker (CD 11c)","longName":"2960425","preferredDefinition":"DC marker (CD 11c)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"781490A4-51BF-A25E-E040-BB89AD432624","latestVersionIndicator":"Yes","beginDate":"2009-11-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"781490A4-51D8-A25E-E040-BB89AD432624","beginDate":"2009-11-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-11","modifiedBy":"ONEDATA","dateModified":"2009-11-11","deletedIndicator":"No"},{"value":"HLA-DR","valueDescription":"HLA-DR Antigen","ValueMeaning":{"publicId":"2829707","version":"1","preferredName":"HLA-DR Antigen","longName":"2829707","preferredDefinition":"Encoded by multiple HLA-DRA and HLA-DRB genes in a complex variable 5 cM region of MHC between HLA-B and -D, HLA-DR Antigens are Class II histocompatibility transmembrane glycoprotein heterodimers of alpha (heavy, 35-kD) and beta (light, 27-kD) chains. Located predominantly on B cells and macrophages, HLA-DR antigens function in antigen presentation to regulatory T cells in the immune response and in self/nonself discrimination. Invariant alpha and polymorphic beta chains have glycosylated N-termini, hydrophobic membrane regions, and hydrophilic C-termini. The heterodimer consists of 4 extracellular domains; invariant alpha-1, polymorphic N-terminal beta-1, and conserved Ig-like alpha-2 and beta-2. Alpha-1 and alpha-2 contain disulfide loops. Beta-1 contains 2 small variable regions. Alpha sequences have relatively simple structure; beta chains carry the major polymorphic determinants. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HLA-DR Antigen","conceptCode":"C16692","definition":"Encoded by multiple HLA-DRA and HLA-DRB genes in a complex variable 5 cM region of MHC between HLA-B and -D, HLA-DR Antigens are Class II histocompatibility transmembrane glycoprotein heterodimers of alpha (heavy, 35-kD) and beta (light, 27-kD) chains. Located predominantly on B cells and macrophages, HLA-DR antigens function in antigen presentation to regulatory T cells in the immune response and in self/nonself discrimination. Invariant alpha and polymorphic beta chains have glycosylated N-termini, hydrophobic membrane regions, and hydrophilic C-termini. The heterodimer consists of 4 extracellular domains; invariant alpha-1, polymorphic N-terminal beta-1, and conserved Ig-like alpha-2 and beta-2. Alpha-1 and alpha-2 contain disulfide loops. Beta-1 contains 2 small variable regions. Alpha sequences have relatively simple structure; beta chains carry the major polymorphic determinants.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"61694C36-36F7-DC55-E040-BB89AD43020E","latestVersionIndicator":"Yes","beginDate":"2009-01-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-01-26","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"781490A4-51EC-A25E-E040-BB89AD432624","beginDate":"2009-11-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-11","modifiedBy":"ONEDATA","dateModified":"2009-11-11","deletedIndicator":"No"},{"value":"NK Cells (CD 56+)","valueDescription":"NK Cells (CD 56+)","ValueMeaning":{"publicId":"2960426","version":"1","preferredName":"NK Cells (CD 56+)","longName":"2960426","preferredDefinition":"NK Cells (CD 56+)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"781490A4-51F7-A25E-E040-BB89AD432624","latestVersionIndicator":"Yes","beginDate":"2009-11-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"781490A4-5210-A25E-E040-BB89AD432624","beginDate":"2009-11-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-11","modifiedBy":"ONEDATA","dateModified":"2009-11-11","deletedIndicator":"No"},{"value":"Monocytes (CD 14+)","valueDescription":"Monocytes (CD 14+)","ValueMeaning":{"publicId":"2960427","version":"1","preferredName":"Monocytes (CD 14+)","longName":"2960427","preferredDefinition":"Monocytes (CD 14+)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"781490A4-521A-A25E-E040-BB89AD432624","latestVersionIndicator":"Yes","beginDate":"2009-11-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"781490A4-5233-A25E-E040-BB89AD432624","beginDate":"2009-11-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-11","modifiedBy":"ONEDATA","dateModified":"2009-11-11","deletedIndicator":"No"},{"value":"B Lymphocytes (CD 19+)","valueDescription":"B Lymphocytes (CD 19+)","ValueMeaning":{"publicId":"2960428","version":"1","preferredName":"B Lymphocytes (CD 19+)","longName":"2960428","preferredDefinition":"B Lymphocytes (CD 19+)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"781490A4-523D-A25E-E040-BB89AD432624","latestVersionIndicator":"Yes","beginDate":"2009-11-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"781490A4-5256-A25E-E040-BB89AD432624","beginDate":"2009-11-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-11","modifiedBy":"ONEDATA","dateModified":"2009-11-11","deletedIndicator":"No"},{"value":"T Lymphocytes (CD 3+)","valueDescription":"T Lymphocytes (CD 3+)","ValueMeaning":{"publicId":"2960429","version":"1","preferredName":"T Lymphocytes (CD 3+)","longName":"2960429","preferredDefinition":"T Lymphocytes (CD 3+)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"781490A4-5260-A25E-E040-BB89AD432624","latestVersionIndicator":"Yes","beginDate":"2009-11-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"781490A4-5279-A25E-E040-BB89AD432624","beginDate":"2009-11-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-11","modifiedBy":"ONEDATA","dateModified":"2009-11-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008547","version":"1","preferredName":"Specimen Characteristics","preferredDefinition":"attributes of a patient's laboratory sample, including the source, condition, and fixative.","longName":"SPEC_CHAR","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22908C4-638F-4A74-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2960423","version":"1","preferredName":"Lineage Biomarker Name","preferredDefinition":"Descent in a line from a common progenitor or source.:Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc:The words or language units by which a thing is known.","longName":"C60792:C16342:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lineage","conceptCode":"C60792","definition":"Descent in a line from a common progenitor or source.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Biomarker","conceptCode":"C16342","definition":"A characteristic that can be objectively measured and serves as an indicator for normal biologic processes, pathogenic processes, state of health or disease, the risk for disease development and/or prognosis, or responsiveness to a particular therapeutic intervention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"781490A4-5199-A25E-E040-BB89AD432624","latestVersionIndicator":"Yes","beginDate":"2009-11-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-11","modifiedBy":"ONEDATA","dateModified":"2009-11-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"781490A4-51AA-A25E-E040-BB89AD432624","latestVersionIndicator":"Yes","beginDate":"2009-11-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-11","modifiedBy":"REEVESD","dateModified":"2009-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2811715","version":"1","longName":"Duke University","context":"NCIP"},{"publicId":"2812724","version":"1","longName":"Duke U New CDEs","context":"NCIP"}]},{"publicId":"3886752","version":"1","longName":"For Review","context":"DCI","ClassificationSchemeItems":[{"publicId":"3891931","version":"1","longName":"For Review","context":"DCI"}]}],"AlternateNames":[{"name":"DCI","type":"USED_BY","context":"DCI"}],"ReferenceDocuments":[{"name":"Lineage Markers","type":"Preferred Question Text","description":"Lineage Markers","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"781490A4-5283-A25E-E040-BB89AD432624","latestVersionIndicator":"Yes","beginDate":"2009-11-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-11","modifiedBy":"ZHANGWE","dateModified":"2013-09-13","changeDescription":"Curated to support Duke University adoption of C3D","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}